Transgene and BioInvent extend OV development for solid tumor collaboration

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Fizkes)
(Image: Getty/Fizkes)

Related tags: solid tumor, Collaboration, Antibody, Antibody drug conjugates, Oncology

Transgene and BioInvent will extend their collaboration to co-develop multi-functional oncolytic viruses for the treatment of solid tumors.

BioInvent, a biotech focused on the discovery and development of immuno-regulatory antibodies for oncology, has agreed to extend its collaboration with the virus-based immunotherapies company Transgene.

The two companies will continue to work to encode undisclosed antibodies sequences to treat solid tumors and develop multi-functional oncolytic viruses​ (OVs).  

A spokesperson for Transgene told us that the current collaboration, initiated in December 2017, is “highly productive”​ and this extension will further expand Transgene’s portfolio of OVs in development.

Transgene will continue to contribute its OV design, non-antibody transgenes, and its engineered vaccinia virus (TK-, RR-) backbone.

This vaccina virus backbone forms the basis of the company’s Invir.IO platform, which will enable continued development through the collaboration as it will be used to create multi-functional OV.

BioInvent will provide its experience in antibody and cancer biology research, and multiple antibodies sequences generated through its n-CoDeR/F.I.R.S.T.TM platforms.

Collaboration developments

The partners suggest multifunctional OVs developed could be significantly more effective than co-administration of an OV and antibody together.

“Encoding BioInvent’s antibodies sequences in Transgene’s proprietary Invir.IO platform, for a direct expression into the tumor, will have several key advantages: it will deliver improved efficacy compared to administering both components together and it will have much better tolerability by limiting the systemic antibody levels in peripheral non-tumor compartments,”​ Transgene’s spokesperson explained.

The spokesperson added that the first Invir.IO OV candidate is expected to enter the clinic in 2020 and will be the first of multiple therapeutic OVs that Transgene intends to develop for solid tumor types.

Initial data from this collaboration showed the OV was able to ensure the expression of BioInvent’s anti-CTLA-4 antibody in the tumor with low systemic exposure, as well as improved efficacy and safety compared to the combination of antibody and non-armed corresponding oncolytic virus given individually in pre-clinical models.

Research and development costs, as well as revenues and royalties from the multifunctional OVs, generated through this collaboration will be shared 50:50. No other financial or logistical details pertaining to the extended agreement are disclosed.

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars